X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (27) 27
male (24) 24
psychiatry (23) 23
female (22) 22
adult (21) 21
index medicus (20) 20
middle aged (20) 20
pharmacology & pharmacy (18) 18
double-blind method (17) 17
cross-over studies (16) 16
abuse potential (11) 11
young adult (11) 11
adolescent (10) 10
dose-response relationship, drug (9) 9
pharmacokinetics (9) 9
analysis (8) 8
clinical neurology (7) 7
clinical trials (7) 7
dopamine (7) 7
drug abuse (7) 7
liability (6) 6
abuse liability (5) 5
alprazolam (5) 5
analgesics, opioid - administration & dosage (5) 5
analgesics, opioid - adverse effects (5) 5
dextromethorphan (5) 5
double-blind (5) 5
drug interactions (5) 5
liability assessment (5) 5
oxycodone (5) 5
pharmacotherapy (5) 5
research (5) 5
addiction (4) 4
c-oxidation (4) 4
cannabidiol (4) 4
central nervous system (4) 4
cigarette-smoking (4) 4
clinical (4) 4
dosage and administration (4) 4
hypnotics and sedatives - administration & dosage (4) 4
nicotine - metabolism (4) 4
opioid (4) 4
opioids (4) 4
pharmacology/toxicology (4) 4
quinidine (4) 4
safety (4) 4
smoking (4) 4
substance abuse (4) 4
substance-related disorders (4) 4
administration, intranasal (3) 3
administration, oral (3) 3
alprazolam - administration & dosage (3) 3
alprazolam - adverse effects (3) 3
alprazolam - pharmacology (3) 3
analgesics, opioid - pharmacokinetics (3) 3
animals (3) 3
aryl hydrocarbon hydroxylases - genetics (3) 3
behavioral sciences (3) 3
cannabinoid (3) 3
central nervous system depressants - pharmacology (3) 3
central nervous system stimulants - administration & dosage (3) 3
central nervous system stimulants - pharmacokinetics (3) 3
cocaine (3) 3
cytochrome p-450 cyp2a6 (3) 3
delayed-action preparations - administration & dosage (3) 3
delta-9-tetrahydrocannabinol (3) 3
drug liking (3) 3
drug users - psychology (3) 3
drug-related side effects and adverse reactions (3) 3
epilepsy (3) 3
ethanol (3) 3
extended release (3) 3
human liver-microsomes (3) 3
hypnotics and sedatives - adverse effects (3) 3
hypnotics and sedatives - pharmacology (3) 3
medicine & public health (3) 3
methylphenidate - pharmacokinetics (3) 3
mixed function oxygenases - genetics (3) 3
opioid-related disorders - prevention & control (3) 3
oral delta-tetrahydrocannabinol (3) 3
oxycodone - administration & dosage (3) 3
oxycodone - adverse effects (3) 3
partial-onset seizures (3) 3
pharmacology (3) 3
risk factors (3) 3
street drugs - adverse effects (3) 3
subjective (3) 3
tetrahydrocannabinol (3) 3
abuse (2) 2
abuse-deterrent formulations (2) 2
abuse-deterrent formulations - adverse effects (2) 2
acetamides - administration & dosage (2) 2
adults (2) 2
alcohol dependence (2) 2
amphetamine (2) 2
analgesics (2) 2
analgesics, opioid - chemistry (2) 2
anesthesiology (2) 2
anticonvulsants - administration & dosage (2) 2
anticonvulsants - adverse effects (2) 2
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2004, ISBN 0612944816
Variation in nicotine metabolism and cytochromes P450 (CYPs) may alter smoking risk and behaviour. Sources of regulatory variation in CYP2A (and CYP2B) and... 
Health Sciences, Toxicology | Health Sciences, Pharmacology
eBook
Epilepsy & Behavior, ISSN 1525-5050, 01/2018, Volume 78, pp. 194 - 201
Brivaracetam is a new antiepileptic drug indicated for adjunctive treatment of focal seizures in adults at a dose of 50–200 mg/day taken in two equal doses.... 
Antiepileptic drug | Alprazolam | Subjective measures | Brivaracetam | Abuse potential | Levetiracetam | SAFETY | PSYCHIATRY | CLINICAL NEUROLOGY | PARTIAL-ONSET SEIZURES | LIABILITY ASSESSMENT | CNS PHARMACODYNAMICS | PHARMACOKINETICS | DOUBLE-BLIND | BEHAVIORAL SCIENCES | PLACEBO-CONTROLLED TRIAL | ADJUNCTIVE BRIVARACETAM | ADVERSE EVENT PROFILE | Hypnotics and Sedatives - adverse effects | Central Nervous System Depressants - adverse effects | Humans | Middle Aged | Hypnotics and Sedatives - administration & dosage | Anticonvulsants - administration & dosage | Male | Anticonvulsants - pharmacology | Levetiracetam - adverse effects | Central Nervous System Depressants - pharmacology | Pyrrolidinones - administration & dosage | Young Adult | Anticonvulsants - adverse effects | Alprazolam - administration & dosage | Drug-Related Side Effects and Adverse Reactions | Pyrrolidinones - pharmacology | Adult | Female | Alprazolam - pharmacology | Pyrrolidinones - adverse effects | Double-Blind Method | Alprazolam - adverse effects | Levetiracetam - administration & dosage | Street Drugs - adverse effects | Cross-Over Studies | Euphoria | Adolescent | Central Nervous System Depressants - administration & dosage | Levetiracetam - pharmacology | Hypnotics and Sedatives - pharmacology | Drug abuse | Anticonvulsants | Seizures (Medicine) | Analysis | Central nervous system
Journal Article
Journal Article
Drug and Alcohol Dependence, ISSN 0376-8716, 2014, Volume 140, pp. e199 - e199
Journal Article
Drug and Alcohol Dependence, ISSN 0376-8716, 2013, Volume 140, pp. e121 - e121
Journal Article
Current Pharmaceutical Design, ISSN 1381-6128, 11/2012, Volume 18, Issue 32, pp. 5008 - 5014
Cannabis use is associated with a spectrum of effects including euphoria, relaxation, anxiety, perceptual alterations, paranoia, and impairments in attention... 
Journal Article
Clinical Drug Investigation, ISSN 1173-2563, 2012, Volume 32, Issue 3, pp. 157 - 169
Journal Article
Applied Clinical Trials, ISSN 1064-8542, 05/2013, Volume 22, Issue 5, p. 24
In Phase I studies with healthy volunteers, the primary method used for evaluating the subjective effects of drugs is through the use of subjective... 
Studies | Professional liability | Clinical trials | Nervous system | Pharmaceutical industry
Journal Article
Clinical Drug Investigation, ISSN 1173-2563, 08/2012, Volume 32, Issue 8, pp. e1 - e15
  Background and Objective: Dextromethorphan/quinidine (DMQ) is the first agent indicated for the treatment of pseudobulbar affect. Dextromethorphan, the... 
Journal Article
Journal of clinical psychopharmacology, ISSN 0271-0749, 01/2019, Volume 39, Issue 1, pp. 46 - 56
Background: Cebranopadol is a nociceptin/ orphanin FQ peptide/ opioid receptor agonist with central antinociceptive activity. We hypothesize that this novel... 
NOP/opioid receptor agonist | hydromorphone | abuse potential | cebranopadol | MORPHINE | PSYCHIATRY | ACQUISITION | NOCICEPTIN/ORPHANIN FQ PEPTIDE | LIABILITY | NOP | DRUG-ABUSE | PAIN | FORMULATIONS | PHARMACOLOGY & PHARMACY | RECEPTOR AGONIST | RELEASE HYDROMORPHONE | Hydromorphone | Receptors | Research | Opioids | opioid receptor agonist | Original Contributions
Journal Article
Journal Article
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.